BCM
JSPRW icon

Beryl Capital Management’s Japer Therapeutics Warrants JSPRW Stock Holding History

Beryl Capital Management’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-126,204
Closed -$183K – 218
2020
Q4 		$183K Hold
126,204
– – 0.03% 219
2020
Q3 		$149K Buy
126,204
+60,542
+92% +$61.2K 0.03% 88
2020
Q2 		$66K Buy
+65,662
New +$40.9K 0.01% 54

Other funds holding JSPRW

OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

Beryl Capital Management's JSPRW Position: Q1 2021 in Review

Beryl Capital Management sold out of Japer Therapeutics Warrants (JSPRW) in Q1 2021, closing a stake of 126,204 shares — an estimated $183K sold.

Beryl Capital Management first reported a position in JSPRW in Q2 2020 and held it in 3 quarters. The position peaked at $183K in Q4 2020. 26 funds tracked by Wall St. Rank hold JSPRW as of Q1 2021.

  • Beryl Capital Management reported no remaining Japer Therapeutics Warrants position as of Q1 2021 after selling out during the quarter.
  • Beryl Capital Management sold 126,204 Japer Therapeutics Warrants shares in Q1 2021, an estimated $183K.
  • Beryl Capital Management first reported a position in Japer Therapeutics Warrants in Q2 2020 and held it in 3 quarters.
  • Beryl Capital Management's Japer Therapeutics Warrants position peaked at $183K in Q4 2020.
  • 26 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q1 2021.

Based on Beryl Capital Management's 13F filing for Q1 2021, filed 17 May 2021.